~~<i id='CD8BE2F721'><strike id='CD8BE2F721'><tt id='CD8BE2F721'><pre id='CD8BE2F721'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：comprehensive 2025-09-06 09:54:58 Page View：98

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

comprehensive

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Head of FDA's diagnostics center, who led through Covid, retires

TimothyStenzelledtheFDA'sdiagnosticsdivisionduringtheCovid-19pandemic,astheagencyscrambledtopushthro